Haleon plc

HLN

GB00BMX86B70

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 10:39:08 2024-06-03 EDT			5-day change	1st Jan Change
326.6 ^GBX	+0.46%		+0.56%	+1.26%

06-01	Delaware judge lets more than 70,000 Zantac lawsuits go forward	RE
05-21	Bernstein becomes more optimistic for consumer goods - Henkel upgraded	DP

An unknown buyer completed the acquisition of 4.2% stake in Haleon plc from GSK plc for £1.2 billion.

May 16, 2024

An unknown buyer intended to acquire 4.2% stake in Haleon plc (LSE:HLN) from GSK plc (LSE:GSK) for £1.2 billion on May 16, 2024.

An unknown buyer completed the acquisition of 4.2% stake in Haleon plc (LSE:HLN) from GSK plc (LSE:GSK) on May 17, 2024.

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	GSK PLC	1,610 GBX	-8.86%	-7.40%	91.66B
	HALEON PLC	326.6 GBX	+0.46%	+0.56%	37.78B

Latest news about Haleon plc

Delaware judge lets more than 70,000 Zantac lawsuits go forward	06-01	RE
Bernstein becomes more optimistic for consumer goods - Henkel upgraded	05-21	DP
UK's FTSE 100 Closes Lower Amid Inflation Focus	05-17	MT
GSK Sells Remaining Stake in Haleon for $1.58 Billion	05-17	MT
FTSE 100 slides; Eurozone inflation steady	05-17	AN
London stocks dip as global rates outlook weighs	05-17	RE
GSK sells remaining Haleon stake for GBP1.25 billion	05-17	AN
FTSE 100 lacklustre as Wall Street rally ends	05-17	AN
London stocks lacklustre but set for weekly gains	05-17	RE
Land Securities ups dividend; GSK sells Haleon stake	05-17	AN
GSK Divests Remaining Haleon Stake in GBP1.25 Billion Deal	05-17	MT
GSK Sells Last Haleon Shares for $1.58 Billion	05-17	DJ
GSK raises $1.5 bln from sale of remaining Haleon stake	05-17	RE
GSK Raises About 1.25 Bln Stg Via Haleon Stake Sale	05-17	RE
GSK to Sell Remaining Haleon Stake	05-16	MT
An unknown buyer completed the acquisition of 4.2% stake in Haleon plc from GSK plc for £1.2 billion.	05-16	CI
GSK to Sell Remaining Stake in Haleon Valued at Around $1.27 Billion -- Update	05-16	DJ
GSK intends to sell its remaining stake in Haleon	05-16	RE
GSK to Sell Stake in Haleon Valued at About $1.61 Billion	05-16	DJ
GSK to sell remaining holding in spin-off Haleon	05-16	AN
GSK Plans to Sell 385 Million Haleon Shares	05-16	MT
GSK intends to sell its entire stake in Haleon	05-16	RE
GSK Announces Intention to Sell Approximately 385 Million Shares in Haleon	05-16	CI
GSK Intends To Sell About 385 Mln Shares In Haleon	05-16	RE
An unknown buyer intended to acquire 4.2% stake in Haleon plc from GSK plc for £1.2 billion.	05-15	CI

Chart Haleon plc

Duration

Period

More charts

Company Profile

Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows: - oral health products (27.7%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.; - Pain relief medicines (23.5%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.; - medicines for digestive health (18.9%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.; - respiratory medicines (15.4%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.; - vitamins, minerals and food supplements (14.5%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (40.2%), North America (37.1%), and Asia/Pacific (22.7%).

Sector

Pharmaceuticals

Calendar

2024-06-05 - Deutsche Bank dbAccess Global Consumer Conference

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

HALEON : Q1 profitability beat; guidance unchanged

May 01, 2024 at 12:20 pm

More Strategies

Ratings for Haleon plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.251 GBP

Average target price

3.62 GBP

Spread / Average Target

+11.35%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HALEON PLC	+1.26%	37.78B
ELI LILLY AND COMPANY	+42.15%	739B
NOVO NORDISK A/S	+32.90%	598B
JOHNSON & JOHNSON	-5.13%	353B
MERCK & CO., INC.	+17.94%	318B
ABBVIE INC.	+5.08%	285B
ASTRAZENECA PLC	+16.53%	240B
NOVARTIS AG	+9.46%	210B
ROCHE HOLDING AG	-5.36%	206B
AMGEN INC.	+7.78%	164B

Other Pharmaceuticals

Haleon plc

Equities

HLN

GB00BMX86B70

Pharmaceuticals

An unknown buyer completed the acquisition of 4.2% stake in Haleon plc from GSK plc for £1.2 billion.

Stocks mentioned in the article

EPS Revisions